<DOC>
	<DOCNO>NCT01643330</DOCNO>
	<brief_summary>The purpose trial ass whether MYDICAR reduce frequency and/or delay heart failure relate hospitalization person advance heart failure add maximal optimized therapy .</brief_summary>
	<brief_title>A Study Genetically Targeted Enzyme Replacement Therapy Advanced Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Unless otherwise specify , screen must perform within 30 day prior administration investigational medicinal product Day 0 except note Inclusion Criteria # 1 4 . Subjects must meet follow criterion eligible study : 1 . Negative neutralizing AAV1 antibody ( NAb ) ( titer &lt; 1:2 equivocal ) within 90 day screen . 2 . 1880 year age , inclusive , time signing informed consent . 3 . Chronic systolic HF due ischemic nonischemic cardiomyopathy . Subjects ischemic cardiomyopathy must least one major coronary vessel Thrombolysis Myocardial Infarction ( TIMI ) grade 3 flow . If subject undergone coronary angiography within 2 month , criterion may assess subject randomize undergoes angiography prior plan infusion investigational medicinal product . 1 . Hypertrophic cardiomyopathy exclude . 2 . Toxic alcoholic cardiomyopathy allow long toxin alcohol exposure eliminate sufficient amount limit elapse ruleout spontaneous recovery . 4 . Left ventricular ejection fraction ( LVEF ) ≤35 % anytime 60day window prior administration investigational medicinal product . 5 . Diagnosis New York Heart Association ( NYHA ) class II , III IV HF minimum 90 day prior screen . 6 . Individualized , maximal , optimized HF therapy consistent American College Cardiology ( ACC ) /American Heart Association ( AHA ) European Society Cardiology ( ESC ) practice guideline treatment chronic heart failure ( ACC/AHA/ESC HF guideline ) update time time : 1 . Medical therapy appropriate individual subject include oral diuretic , angiotensinconverting enzyme ( ACE ) inhibitor ( angiotensinreceptor blocker ( ARB ) ACE intolerant ) , tolerate , beta blocker approve dosage label respective package insert . The choice beta blocker limit approved heart failure participate country ( bisoprolol , carvedilol sustain release metoprolol succinate ) . Unless contraindicate tolerated , addition aldosterone antagonist consider absence hyperkalemia significant renal dysfunction accord evolving standard ; final decision discretion investigator . Dosing medication must stable minimum 30 day prior screen , although downtitration diuretic , medically indicate , permit . Enrollment subject deviation combination must preapproved medical monitor . 2 . Resynchronization therapy , clinically indicate accord ACC/AHA/ESC HF guideline , must implant least 6 month prior screen . 3 . Implantable cardioverter defibrillator ( ICD ) , clinically indicate accord ACC/AHA/ESC HF guideline , must implant minimum 30 day prior screen . 4 . Cardiac rehabilitation consistent Agency Health Care Policy Research Clinical Practice Guideline , Number 17 , Cardiac Rehabilitation . This imply potential candidate must enrol cardiac rehabilitation program screening future . 7 . All woman childbearing potential must negative urine pregnancy test prior administration investigational medicinal product agree use adequate contraception ( defined oral injectable contraceptive , intrauterine device , surgical sterilization combination condom spermicide ) limit sexual activity vasectomize partner 3 month administration investigational medicinal product . Men capable fathering child must agree use barrier contraception ( combination condom spermicide ) limit activity postmenopausal , surgically sterilize , contraceptionpracticing partner , 3 month administration investigational medicinal product . 8 . Ability understand comply study requirement evidence provide sign write informed consent form Release Medical Information Form . 9 . Presence least one follow risk factor : 1 . Hospitalization heart failure within 6 month screen , lieu hospitalization , least 2 outpatient intervention intend treatment sign symptom worsen heart failure ( e.g. , intravenous diuretic , peripheral ultrafiltration ) 2 . Nterminal proBtype natriuretic peptide ( NTproBNP ) &gt; 1200 pg/mL ( BNP &gt; 225 pg/mL ) within 30 day screen ; subject atrial fibrillation , NTproBNP &gt; 1600 pg/mL ( BNP &gt; 275 pg/mL ) within 30 day screen 10 . In Germany : Medically indicate diagnostic angiography clinician 's discretion . Subjects meet follow criterion exclude study : 1 . Any intravenous ( IV ) therapy positive inotropes , vasodilator diuretic within 30 day prior screen . 2 . Restrictive cardiomyopathy , obstructive cardiomyopathy , acute myocarditis , pericardial disease , amyloidosis , infiltrative cardiomyopathy , uncorrected thyroid disease discrete LV aneurysm . 3 . Cardiac surgery , percutaneous coronary intervention ( PCI ) valvuloplasty within 30 day prior screen . 4 . Myocardial infarction ( MI ) ( e.g. , ST elevation MI [ STEMI ] large nonSTEMI ) within 90 day prior screen . Large nonSTEMI shall define &gt; 3x upper limit normal ( ULN ) creatinine kinase ( CK ) MB &gt; 5x ULN troponin . 5 . Prior heart transplantation , leave ventricular reduction surgery ( LVRS ) , cardiomyoplasty , passive restraint device ( e.g. , CorCap™ Cardiac Support Device ) , surgically implant leave ventricular assist device ( LVAD ) cardiac shunt . 6 . Likely need immediate heart transplant LVAD implant due hemodynamic instability . 7 . Prior coronary artery bypass grafting ( CABG ) consider ideal inclusion study ; however , potential candidate review casebycase basis . Ideally , orifice graft easy engage catheter graft perfuse significant amount potentially viable myocardium . 8 . Known hypersensitivity contrast agent use angiography ; history , likely need , high dose steroid pretreatment prior contrast angiography . 9 . Significant , opinion investigator , leave main ostial right coronary luminal stenosis . 10 . Liver function test ( alanine amino transferase [ ALT ] , aspartate aminotransferase [ AST ] , alkaline phosphatase ) &gt; 3x ULN within 30 day prior investigational medicinal product administration know intrinsic liver disease ( e.g. , cirrhosis , chronic hepatitis B hepatitis C virus infection ) . 11 . Current likely need hemodialysis within 12 month follow enrollment current glomerular filtration rate ( GFR ) ≤20 mL/minute/1.73 m^2 estimate Modification Diet Renal Disease ( MDRD ) calculation . 12 . Bleeding diathesis thrombocytopenia define platelet count &lt; 50,000 platelets/μL . 13 . Anemia define hemoglobin &lt; 9 g/dL , provide evidence bleeding . 14 . Known AIDS HIV seropositive status , previous diagnosis immunodeficiency absolute neutrophil count &lt; 1000 cells/mm^3 . 15 . Diagnosis , treatment , cancer basal cell carcinoma within last 5 year . ( Past medical history cancer exclusionary long subject diseasefree least 5 year since time diagnosis treatment ) . 16 . Previous participation study gene transfer ; however , study unblinded documentation otherwise exist subject randomize placebo control group receive active gene transfer agent , subject may consider study . 17 . Receiving investigational intervention participate another clinical study within 30 day within 5 halflives investigational drug administration prior screen . Exception may make individual enrol nontherapeutic observational study ( registry ) observational portion therapeutic study sponsor authority authorize enrollment . 18 . Pregnant breastfeeding . 19 . Recent history psychiatric disease , include drug alcohol abuse , likely impair , opinion investigator , subject 's ability comply protocolmandated procedure . 20 . Other concurrent medical condition ( ) , explicitly exclude protocol , could jeopardize safety subject objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Cardiomegaly</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
</DOC>